Frank Samuel, Ondo William, Fahn Stanley, Hunter Christine, Oakes David, Plumb Sandra, Marshall Frederick, Shoulson Ira, Eberly Shirley, Walker Francis, Factor Stewart, Hunt Vicki, Shinaman Aileen, Jankovic Joseph
Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Clin Neuropharmacol. 2008 May-Jun;31(3):127-33. doi: 10.1097/WNF.0b013e3180ca77ea.
To assess tetrabenazine (TBZ) efficacy by evaluating the change in Huntington disease-associated chorea resulting from TBZ treatment withdrawal.
Thirty patients treated in the long term were randomized to 1 of 3 groups assigned to withdraw from TBZ in a double-blind, staggered fashion during a 5-day period.
The chorea scores of subjects withdrawn from TBZ treatment increased by 5.3 units from days 1 to 3, whereas the scores of the group with partial or no withdrawal of TBZ treatment increased by 3.0 units (P = 0.0773). A post hoc analysis of the linear trend was positive for reemergent chorea (P = 0.0486). No serious adverse events were reported after abrupt withdrawal of TBZ treatment.
The trend for reemergence of chorea in patients with Huntington disease who were withdrawn from TBZ treatment is consistent with the findings from previous studies, thus showing the effectiveness of TBZ in reducing chorea.
通过评估停用丁苯那嗪（TBZ）治疗后亨廷顿病相关性舞蹈症的变化来评估丁苯那嗪（TBZ）的疗效。
30例长期接受治疗的患者被随机分为3组中的1组，在5天内以双盲、交错的方式停用TBZ。
从第1天到第3天，停用TBZ治疗的受试者的舞蹈症评分增加了5.3个单位，而部分或未停用TBZ治疗的组的评分增加了3.0个单位（P = 0.0773）。对再发性舞蹈症进行的事后线性趋势分析呈阳性（P = 0.0486）。突然停用TBZ治疗后未报告严重不良事件。
停用TBZ治疗的亨廷顿病患者出现舞蹈症复发的趋势与先前研究的结果一致，从而表明TBZ在减轻舞蹈症方面的有效性。
